BioSpace News Archive

Pfizer and Germany-based BioNTech are collaborating on a messenger RNA vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Biopharma companies from across the globe provide updates on their business and pipelines.

The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.

Despite external factors, there are things to maintain productivity while working remotely. Here are four common work from home problems and how you can avoid them!

ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced the appointment of Victor Sandor, M.D., to its Board of Directors.

The U.S. Food and Drug Administration approved an additional recommended dosage of 400 mg every six weeks for the anti-PD-1 therapy across all adult indications, including as a monotherapy and in combination treatments.

As Tocagen heads into its reverse merger with Forte Biosciences, Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.

Gilead announced topline results from the open-label, Phase III SIMPLE trial looking at 5-day and 10-day dosing of the drug in hospitalized patients with severe disease. It also reported positive data from the National Institute of Allergy and Infectious Diseases’ trial of the drug in COVID-19.

Working from home has its perks, like no commute time and a more flexible schedule. But work from home can help you in keeping connections with co-workers difficult.

Shares of Eagle Pharmaceuticals and Teva Pharmaceuticals are climbing following a favorable ruling in U.S. District Court that protects the patent for cancer drug Bendeka from generic competition through 2031.